Currently, a Phase III study of ivonescimab monotherapy versus pembrolizumab monotherapy ... regimen as first-line treatment for pancreatic cancer. Overall, ivonescimab is engaged in over ...

According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, exhibiting a growth ...

Aethlon's Hemopurifier® is a clinical stage immunotherapeutic device designed to combat cancer. Read the full article at Investorideas.com According to News-Medical.net, "Immunotherapy, which works ...

Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically ...